EC 207-175-4
In FUZION, TREMFYA 100 mg q8w combined remission rose from 28% at Week 24 to 35% at Week 48; 200 mg q4w rates remained stable and safety was consistent through one year.
Phase 2 data show FcRn blocker nipocalimab reduced SLE activity versus placebo, with larger benefit in autoantibody‑positive patients and no new safety signals.
